Corporate Profile for Diatide, Inc., dated July 2, 1999.--(BUSINESS WIRE)-- The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: July 2, 1999
Company Name: Diatide, Inc.
Address: 9 Delta Drive
Londonderry, NH 03053
Main Telephone
Number: 603-437-8970
Internet Home
Page Address
(URL) www.diatide.com
Chief Executive
Officer: Richard T. Dean, Ph.D.
Investor Relations
Contact: Richard T. Dean, Ph.D.
Industry: Biotechnology
Exchange and
symbol: NASDAQ:DITI
-0- Company description: Diatide, Inc., (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DITI DITI Digital Infrared Thermal Imaging ) located in Londonderry, New Hampshire Londonderry, New Hampshire is a town located in the western part of Rockingham County, New Hampshire, USA. The town is bordered on the north by Manchester, New Hampshire and on the east by Derry, New Hampshire. The population was 23,236 at the 2000 census. , is a speciality pharmaceutical company engaged in the discovery and development of proprietary disease-specific pharmaceuticals for the diagnosis and treatment of life-threatening conditions such as cancer, infection and cardiovascular disease. Advances in molecular biology and peptide chemistry have enabled the characterization of cell receptors associated with various active disease states and the structure of peptides that bind to these cell receptors. The combination of these advances and Diatide's proprietary technologies in the areas of peptide engineering and radiolabeling radiolabeling incorporation of a radioactive element into a compound in order to investigate its metabolism, fate and utilization. chemistry has produced a number of small peptides that bind with high affinity and specificity to molecular targets on diseased tissue to which a radioisotope can be attached for diagnostic or therapeutic products. Several of the imaging products ("Techtides") are in late stage development. The Company has receiv! ed approval from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for its lead product AcuTectTM for diagnosing deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. , and a priority status for its second NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any , P829, for imaging malignant tumors in the lung. Additionally, Diatide recently began researching therapeutic applications of the technology focusing on oncology and cardiovascular indications. -0- Stock High/Low 52-Week High: 10.130 52-Week Low: 2 3/4 1998 Revenue: $6,384,659 Net Loss 1998: $10,217,049 -0- |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion